







an Open Access Journal by MDPI

# **Precision Medicine and Molecular Diagnosis for Urogenital Cancer**

Guest Editors:

Dr. Wen-Wei Sung

Dr. Jian-Ri Li

Dr. Chih-Jung Chen

Dr. Cheng-Kuang Yang

Deadline for manuscript submissions:

closed (10 June 2022)

## **Message from the Guest Editors**

Urogenital cancers include tumours of the kidney and bladder, and, in men, of the prostate and testicle pose considerable challenges to the urologist. Recent advances in molecular diagnosis and precision medicine provide more therapeutic strategies and favourable prognoses in patients with urogenital cancers. This Special Issue of the *Journal of Personalized Medicine* aims to explore the latest innovative molecular findings or clinical experience to provide more evidence to support further clinical trials. Studies of basic science, translational, clinical and population-based approaches are encouraged to submit contributions. Our goal is to demonstrate the scientific advances in the field of urogenital cancers and pave the way towards personalized medicine or diagnosis. Both original research and review articles are welcome.













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

## Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

#### **Contact Us**